Top

Published in:

Open Access 01-12-2021 | Review

The m⁶A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis

Authors: Mohammad Burhan Uddin, Zhishan Wang, Chengfeng Yang

Published in: Molecular Cancer | Issue 1/2021

Abstract

The m⁶A RNA methylation is the most prevalent internal modification in mammalian mRNAs which plays critical biological roles by regulating vital cellular processes. Dysregulations of the m⁶A modification due to aberrant expression of its regulatory proteins are frequently observed in many pathological conditions, particularly in cancer. Normal cells undergo malignant transformation via activation or modulation of different oncogenic signaling pathways through complex mechanisms. Accumulating evidence showing regulation of oncogenic signaling pathways at the epitranscriptomic level has added an extra layer of the complexity. In particular, recent studies demonstrated that, in many types of cancers various oncogenic signaling pathways are modulated by the m⁶A modification in the target mRNAs as well as noncoding RNA transcripts. m⁶A modifications in these RNA molecules control their fate and metabolism by regulating their stability, translation or subcellular localizations. In this review we discussed recent exciting studies on oncogenic signaling pathways that are modulated by the m⁶A RNA modification and/or their regulators in cancer and provided perspectives for further studies. The regulation of oncogenic signaling pathways by the m⁶A modification and its regulators also render them as potential druggable targets for the treatment of cancer.

Saletore Y, Meyer K, Korlach J, Vilfan ID, Jaffrey S, Mason CE. The birth of the Epitranscriptome: deciphering the function of RNA modifications. Genome Biol. 2012;13(10):175. https://doi.org/10.1186/gb-2012-13-10-175.CrossRefPubMedPubMedCentral

He C. Grand challenge commentary: RNA epigenetics? Nat Chem Biol. 2010;6(12):863–5. https://doi.org/10.1038/nchembio.482.CrossRefPubMed

Yu S, Li X, Liu S, Yang R, Liu X, Wu S. N⁶-methyladenosine: a novel RNA imprint in human cancer. Front Oncol. 2019;9. https://doi.org/10.3389/fonc.2019.01407.

Balacco DL, Soller M. The m⁶A writer: rise of a machine for growing tasks. Biochemistry. 2018;58(5):363–78. https://doi.org/10.1021/acs.biochem.8b01166.CrossRefPubMed

Uddin MB, Wang Z, Yang C. Dysregulations of functional RNA modifications in cancer, cancer stemness and cancer therapeutics. Theranostics. 2020;10(7):3164–89. https://doi.org/10.7150/thno.41687.CrossRefPubMedPubMedCentral

Bokar JA, Rath-Shambaugh ME, Ludwiczak R, Narayan P, Rottman F. Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J Biol Chem. 1994;269(26):17697–704. https://doi.org/10.1016/S0021-9258(17)32497-3.CrossRefPubMed

Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA N⁶-adenosine methylation. Nat Chem Biol. 2014;10(2):93–5. https://doi.org/10.1038/nchembio.1432.CrossRefPubMed

Ping X-L, Sun B-F, Wang L, Xiao W, Yang X, Wang W-J, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2):177–89. https://doi.org/10.1038/cr.2014.3.CrossRefPubMedPubMedCentral

Patil DP, Chen C-K, Pickering BF, Chow A, Jackson C, Guttman M, et al. m⁶A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369–73. https://doi.org/10.1038/nature19342.CrossRefPubMedPubMedCentral

10.

Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z, et al. VIRMA mediates preferential m⁶A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4(1):1–17.CrossRef

11.

Warda AS, Kretschmer J, Hackert P, Lenz C, Urlaub H, Höbartner C, et al. Human METTL16 is a N⁶-methyladenosine (m⁶A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017;18(11):2004–14. https://doi.org/10.15252/embr.201744940.CrossRefPubMedPubMedCentral

12.

Liu N, Pan T. RNA epigenetics. Transl Res. 2015;165(1):28–35. https://doi.org/10.1016/j.trsl.2014.04.003.CrossRefPubMed

13.

Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885–7. https://doi.org/10.1038/nchembio.687.CrossRefPubMedPubMedCentral

14.

Fu Y, Jia G, Pang X, Wang RN, Wang X, Li CJ, et al. FTO-mediated formation of N⁶-hydroxymethyladenosine and N⁶-formyladenosine in mammalian RNA. Nat Commun. 2013;4(1):1–8.

15.

Yue Y, Liu J, He C. RNA N⁶-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 2015;29(13):1343–55. https://doi.org/10.1101/gad.262766.115.CrossRefPubMedPubMedCentral

16.

Yang G, Sun Z, Zhang N. Reshaping the role of m6A modification in cancer transcriptome: a review. Cancer Cell Int. 2020;20(1):1–10.CrossRef

17.

Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K, et al. AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017;7(1):42271. https://doi.org/10.1038/srep42271.CrossRefPubMedPubMedCentral

18.

Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m⁶A RNA methylomes revealed by m⁶A-seq. Nature. 2012;485(7397):201–6. https://doi.org/10.1038/nature11112.CrossRefPubMed

19.

Xu C, Wang X, Liu K, Roundtree IA, Tempel W, Li Y, et al. Structural basis for selective binding of m⁶A RNA by the YTHDC1 YTH domain. Nat Chem Biol. 2014;10(11):927–9. https://doi.org/10.1038/nchembio.1654.CrossRefPubMed

20.

Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, et al. Ythdc2 is an N⁶-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27(9):1115–27. https://doi.org/10.1038/cr.2017.99.CrossRefPubMedPubMedCentral

21.

Liu N, Dai Q, Zheng G, He C, Parisien M, Pan T. N⁶-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518(7540):560–4. https://doi.org/10.1038/nature14234.CrossRefPubMedPubMedCentral

22.

Alarcón CR, Goodarzi H, Lee H, Liu X, Tavazoie S, Tavazoie SF. HNRNPA2B1 is a mediator of m⁶A-dependent nuclear RNA processing events. Cell. 2015;162(6):1299–308. https://doi.org/10.1016/j.cell.2015.08.011.CrossRefPubMedPubMedCentral

23.

Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, et al. 5′ UTR m⁶A promotes cap-independent translation. Cell. 2015;163(4):999–1010. https://doi.org/10.1016/j.cell.2015.10.012.CrossRefPubMedPubMedCentral

24.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N⁶-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–95. https://doi.org/10.1038/s41556-018-0045-z.CrossRefPubMedPubMedCentral

25.

Lewis CJ, Pan T, Kalsotra A. RNA modifications and structures cooperate to guide RNA-protein interactions. Nat Rev Mol Cell Biol. 2017;18(3):202–10. https://doi.org/10.1038/nrm.2016.163.CrossRefPubMedPubMedCentral

26.

Liu N, Pan T. N⁶-methyladenosine-encoded epitranscriptomics. Nat Struct Mol Biol. 2016;23(2):98–102. https://doi.org/10.1038/nsmb.3162.CrossRefPubMed

27.

Delaunay S, Frye M. RNA modifications regulating cell fate in cancer. Nat Cell Biol. 2019;21(5):552–9. https://doi.org/10.1038/s41556-019-0319-0.CrossRefPubMed

28.

Zhou KI, Pan T. An additional class of m⁶A readers. Nat Cell Biol. 2018;20(3):230–2. https://doi.org/10.1038/s41556-018-0046-y.CrossRefPubMedPubMedCentral

29.

Cui X, Wang Z, Li J, Zhu J, Ren Z, Zhang D, et al. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway. Cell Prolif. 2020;53(3):e12768.CrossRef

30.

Liu L, Wang J, Sun G, Wu Q, Ma J, Zhang X, et al. m⁶A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma. Mol Cancer. 2019;18(1):1–13.CrossRef

31.

Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, et al. N⁶-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res. 2019;79(11):2812–20. https://doi.org/10.1158/0008-5472.CAN-18-3592.CrossRefPubMedPubMedCentral

32.

Miao W, Chen J, Jia L, Ma J, Song D. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. Biochem Biophys Res Commun. 2019;516(3):719–25. https://doi.org/10.1016/j.bbrc.2019.06.128.CrossRefPubMed

33.

Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi Y, et al. m⁶A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling. Mol Cancer. 2020;19(1):1–15.CrossRef

34.

Bai Y, Yang C, Wu R, Huang L, Song S, Li W, et al. YTHDF1 regulates Tumorigenicity and Cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 2019;9:332. https://doi.org/10.3389/fonc.2019.00332.CrossRefPubMedPubMedCentral

35.

Pi J, Wang W, Ji M, Wang X, Wei X, Jin J, et al. YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7. Cancer Res. 2020:canres.0066.2020. https://doi.org/10.1158/0008-5472.CAN-20-0066.

36.

Zhang C, Zhang M, Ge S, Huang W, Lin X, Gao J, et al. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer. Cancer Med. 2019;8(10):4766–81. https://doi.org/10.1002/cam4.2360.CrossRefPubMedPubMedCentral

37.

Liu J, Eckert MA, Harada BT, Liu S-M, Lu Z, Yu K, et al. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20(9):1074–83. https://doi.org/10.1038/s41556-018-0174-4.CrossRefPubMedPubMedCentral

38.

Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang Q, et al. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett. 2012;319(1):89–97. https://doi.org/10.1016/j.canlet.2011.12.033.CrossRefPubMed

39.

Bi X, Lv X, Liu D, Guo H, Yao G, Wang L, et al. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway. Cancer Gene Ther. 2020:1–15.

40.

Zhao Q, Zhao Y, Hu W, Zhang Y, Wu X, Lu J, et al. m⁶A RNA modification modulates PI3K/Akt/mTOR signal pathway in gastrointestinal cancer. Theranostics. 2020;10(21):9528–43. https://doi.org/10.7150/thno.42971.CrossRefPubMedPubMedCentral

41.

He J, Li Z, Zhuoxian R, Gao J, Mu Y, Guan Y-D, et al. m⁶A reader YTHDC2 promotes radiotherapy resistance of nasopharyngeal carcinoma via activating IGF1R/AKT/S6 signaling axis. Front Oncol. 2020;10:1166. https://doi.org/10.3389/fonc.2020.01166.CrossRefPubMedPubMedCentral

42.

Li X, Tang J, Huang W, Wang F, Li P, Qin C, et al. The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma. Oncotarget. 2017;8(56):96103–16. https://doi.org/10.18632/oncotarget.21726.CrossRefPubMedPubMedCentral

43.

Shi X, Ran L, Liu Y, Zhong SH, Zhou PP, Liao MX, et al. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway. Oncol Rep. 2018;39(3):939–50.PubMedPubMedCentral

44.

Liu Y, Wang R, Zhang L, Li J, Lou K, Shi B. The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett. 2017;13(6):4685–90. https://doi.org/10.3892/ol.2017.6038.CrossRefPubMedPubMedCentral

45.

Yu H-L, Ma X-D, Tong J-F, Li J-Q, Guan X-J, Yang J-H. WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells. OncoTargets Ther. 2019;12:6191.CrossRef

46.

Chen J, Sun Y, Xu X, Wang D, He J, Zhou H, et al. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Cell Cycle. 2017;16(23):2259–71. https://doi.org/10.1080/15384101.2017.1380125.CrossRefPubMedPubMedCentral

47.

Chen M, Wei L, Law CT, Tsang FHC, Shen J, Cheng CLH, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018;67(6):2254–70. https://doi.org/10.1002/hep.29683.CrossRefPubMed

48.

Xu J, Chen Q, Tian K, Liang R, Chen T, Gong A, et al. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation. Oncol Rep. 2020;44(3):973–86. https://doi.org/10.3892/or.2020.7665.CrossRefPubMedPubMedCentral

49.

Jiang L, Chen T, Xiong L, Xu JH, Gong AY, Dai B, et al. Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation. Oncol Lett. 2020;20(3):2191–8. https://doi.org/10.3892/ol.2020.11794.CrossRefPubMedPubMedCentral

50.

Gong D, Zhang J, Chen Y, Xu Y, Ma J, Hu G, et al. The m⁶A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca 2+ influx modulating ERK1/2 phosphorylation and MMP9 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):233. https://doi.org/10.1186/s13046-019-1223-y.CrossRefPubMedPubMedCentral

51.

Deng R, Cheng Y, Ye S, Zhang J, Huang R, Li P, et al. m⁶A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways. OncoTargets Ther. 2019;12:4391–402. https://doi.org/10.2147/OTT.S201052.CrossRef

52.

Peng W, Li J, Chen R, Gu Q, Yang P, Qian W, et al. Upregulated METTL3 promotes metastasis of colorectal cancer via miR-1246/SPRED2/MAPK signaling pathway. J Exp Clin Cancer Res. 2019;38(1):393. https://doi.org/10.1186/s13046-019-1408-4.CrossRefPubMedPubMedCentral

53.

Chen SL, Liu LL, Wang CH, Lu SX, Yang X, He YF, et al. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways. Mol Oncol. 2020;14(2):373–86. https://doi.org/10.1002/1878-0261.12593.CrossRefPubMed

54.

Xie J-W, Huang X-B, Chen Q-Y, Ma Y-B, Zhao Y-J, Liu L-C, et al. m⁶A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling. Mol Cancer. 2020;19(1):1–15.CrossRef

55.

Yu T, Xu Y, Sun T, Huang D, Cao F, Gao X, et al. YTHDC2 promotes the apoptosis of colorectal cancer cells through the p38MAPK signaling pathway. 2020.CrossRef

56.

Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, et al. YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2019;442:252–61. https://doi.org/10.1016/j.canlet.2018.11.006.CrossRefPubMed

57.

Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang Y, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m⁶A-YTHDF2-dependent manner. Mol Cancer. 2020;19:1–19.CrossRef

58.

Zhou J, Wang J, Hong B, Ma K, Xie H, Li L, et al. Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma–a retrospective study using TCGA database. Aging (Albany NY). 2019;11(6):1633.CrossRef

59.

Yang W, Duan L, Zhao X, Wang X, Li Y, Niu L, et al. Identification and validation of a novel prognostic index based on m6A RNA methylation regulators in esophageal carcinoma. 2020.CrossRef

60.

Uddin MB, Roy KR, Hosain SB, Khiste SK, Hill RA, Jois SD, et al. An N⁶-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem Pharmacol. 2019;160:134–45. https://doi.org/10.1016/j.bcp.2018.12.014.CrossRefPubMed

61.

Li J, Han Y, Zhang H, Qian Z, Jia W, Gao Y, et al. The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Biochem Biophys Res Commun. 2019;512(3):479–85. https://doi.org/10.1016/j.bbrc.2019.03.093.CrossRefPubMed

62.

Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, et al. m⁶A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12(1):135. https://doi.org/10.1186/s13045-019-0830-6.CrossRefPubMedPubMedCentral

63.

Jin D, Guo J, Wu Y, Yang L, Wang X, Du J, et al. m⁶A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC. Mol Cancer. 2020;19(1):1–24.CrossRef

64.

Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m⁶A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62(3):335–45. https://doi.org/10.1016/j.molcel.2016.03.021.CrossRefPubMedPubMedCentral

65.

Chen X, Xu M, Xu X, Zeng K, Liu X, Sun L, et al. METTL14 suppresses CRC progression via regulating N6-Methyladenosine-dependent primary miR-375 processing. Mol Ther. 2020;28(2):599–612. https://doi.org/10.1016/j.ymthe.2019.11.016.CrossRefPubMed

66.

Zheng Q, Lin Z, Li X, Xin X, Wu M, An J, et al. Inflammatory cytokine IL6 cooperates with CUDR to aggravate hepatocyte-like stem cells malignant transformation through NF-κB signaling. Sci Rep. 2016;6(1):36843. https://doi.org/10.1038/srep36843.CrossRefPubMedPubMedCentral

67.

Chen Z, Wu L, Zhou J, Lin X, Peng Y, Ge L, et al. N6-methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming. Theranostics. 2020;10(8):3382–96. https://doi.org/10.7150/thno.40144.CrossRefPubMedPubMedCentral

68.

Jiang Y, Wan Y, Gong M, Zhou S, Qiu J, Cheng W. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway. J Cell Mol Med. 2020;24(11):6137–48. https://doi.org/10.1111/jcmm.15228.CrossRefPubMedPubMedCentral

69.

Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The m⁶A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 2019;38(19):3667–80. https://doi.org/10.1038/s41388-019-0683-z.CrossRefPubMed

70.

Cai J, Yang F, Zhan H, Situ J, Li W, Mao Y, et al. RNA m⁶A methyltransferase METTL3 promotes the growth of prostate cancer by regulating hedgehog pathway. OncoTargets Ther. 2019;12:9143–52. https://doi.org/10.2147/OTT.S226796.CrossRef

71.

Visvanathan A, Patil V, Abdulla S, Hoheisel JD, Somasundaram K. N⁶-Methyladenosine landscape of glioma stem-like cells: METTL3 is essential for the expression of actively transcribed genes and sustenance of the oncogenic signaling. Genes. 2019;10(2):141. https://doi.org/10.3390/genes10020141.CrossRefPubMedCentral

72.

Lin X, Chai G, Wu Y, Li J, Chen F, Liu J, et al. RNA m⁶A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of snail. Nat Commun. 2019;10(1):1–13.CrossRef

73.

Xu H, Wang H, Zhao W, Fu S, Li Y, Ni W, et al. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating snail mRNA homeostasis in hepatocellular carcinoma. Theranostics. 2020;10(13):5671–86. https://doi.org/10.7150/thno.42539.CrossRefPubMedPubMedCentral

74.

Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–205. https://doi.org/10.1016/j.cell.2012.05.012.CrossRefPubMed

75.

Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20(1):781–810. https://doi.org/10.1146/annurev.cellbio.20.010403.113126.CrossRefPubMed

76.

Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10(1):101. https://doi.org/10.1186/s13045-017-0471-6.CrossRefPubMedPubMedCentral

77.

MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. https://doi.org/10.1016/j.devcel.2009.06.016.CrossRefPubMedPubMedCentral

78.

Chamcheu JC, Roy T, Uddin MB, Banang-Mbeumi S, Chamcheu R-CN, Walker AL, et al. Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy. Cells. 2019;8(8):803. https://doi.org/10.3390/cells8080803.CrossRefPubMedCentral

79.

Jason S, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050–60.CrossRef

80.

Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014;4:64.CrossRef

81.

Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76. https://doi.org/10.1016/j.cell.2017.02.004.CrossRefPubMedPubMedCentral

82.

Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281–3. https://doi.org/10.1242/jcs.00963.CrossRefPubMed

83.

Li WX. Canonical and non-canonical JAK–STAT signaling. Trends Cell Biol. 2008;18(11):545–51. https://doi.org/10.1016/j.tcb.2008.08.008.CrossRefPubMedPubMedCentral

84.

Quintás-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19(8):1933–40. https://doi.org/10.1158/1078-0432.CCR-12-0284.CrossRefPubMedPubMedCentral

85.

Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018;27(12):1984–2009. https://doi.org/10.1002/pro.3519.CrossRefPubMedPubMedCentral

86.

Luo N, Balko JM. Role of JAK-STAT pathway in cancer signaling. Predictive biomarkers in oncology: Springer; 2019. p. 311–9. https://doi.org/10.1007/978-3-319-95228-4_26.CrossRef

87.

Li H-B, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, et al. m⁶A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017;548(7667):338–42. https://doi.org/10.1038/nature23450.CrossRefPubMedPubMedCentral

88.

Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer. 2014;120(22):3446–56. https://doi.org/10.1002/cncr.28864.CrossRefPubMedPubMedCentral

89.

Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90. https://doi.org/10.1038/sj.onc.1210421.CrossRefPubMed

90.

Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta (BBA) Mol Cell Res. 2011;1813(9):1619–33.CrossRef

91.

Huang P, Han J, Hui L. MAPK signaling in inflammation-associated cancer development. Protein Cell. 2010;1(3):218–26. https://doi.org/10.1007/s13238-010-0019-9.CrossRefPubMedPubMedCentral

92.

Wagner EF, Nebreda ÁR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49. https://doi.org/10.1038/nrc2694.CrossRefPubMed

93.

Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359–70. https://doi.org/10.1038/nrc3711.CrossRefPubMedPubMedCentral

94.

Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006;21(3):307–15. https://doi.org/10.1016/j.molcel.2006.01.020.CrossRefPubMedPubMedCentral

95.

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10. https://doi.org/10.1038/35042675.CrossRefPubMed

96.

Kwok C-T, Marshall AD, Rasko JE, Wong JJ. Genetic alterations of m⁶A regulators predict poorer survival in acute myeloid leukemia. J Hematol Oncol. 2017;10(1):39. https://doi.org/10.1186/s13045-017-0410-6.CrossRefPubMedPubMedCentral

97.

Roy KR, Uddin MB, Roy SC, Hill RA, Marshall J, Li YT, et al. Gb3-cSrc complex in glycosphingolipid-enriched microdomains contributes to the expression of p53 mutant protein and cancer drug resistance via β-catenin activated RNA-methylation. FASEB BioAdv. 2020;2(11):653–67. https://doi.org/10.1096/fba.2020-00044.CrossRefPubMedPubMedCentral

98.

Yu F-X, Guan K-L. The hippo pathway: regulators and regulations. Genes Dev. 2013;27(4):355–71. https://doi.org/10.1101/gad.210773.112.CrossRefPubMedPubMedCentral

99.

Zhao B, Li L, Guan K-L. Hippo signaling at a glance. J Cell Sci. 2010;123(23):4001–6. https://doi.org/10.1242/jcs.069070.CrossRefPubMedPubMedCentral

100.

Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94(4):1287–312. https://doi.org/10.1152/physrev.00005.2014.CrossRefPubMed

101.

Sebio A, Lenz H-J. Molecular pathways: hippo signaling, a critical tumor suppressor. Clin Cancer Res. 2015;21(22):5002–7. https://doi.org/10.1158/1078-0432.CCR-15-0411.CrossRefPubMedPubMedCentral

102.

Han Y. Analysis of the role of the hippo pathway in cancer. J Transl Med. 2019;17(1):116. https://doi.org/10.1186/s12967-019-1869-4.CrossRefPubMedPubMedCentral

103.

Aik W, Demetriades M, Hamdan MK, Bagg EA, Yeoh KK, Lejeune C, et al. Structural basis for inhibition of the fat mass and obesity associated protein (FTO). J Med Chem. 2013;56(9):3680–8. https://doi.org/10.1021/jm400193d.CrossRefPubMed

104.

Selberg S, Blokhina D, Aatonen M, Koivisto P, Siltanen A, Mervaala E, et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3–14-WTAP complex active site. Cell Rep. 2019;26(13):3762–71. e5.CrossRef

105.

Niu Y, Wan A, Lin Z, Lu X, Wan G. N⁶-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development. Acta Pharm Sin B. 2018;8(6):833–43. https://doi.org/10.1016/j.apsb.2018.06.001.CrossRefPubMedPubMedCentral

106.

Huang Y, Yan J, Li Q, Li J, Gong S, Zhou H, et al. Meclofenamic acid selectively inhibits FTO demethylation of m⁶A over ALKBH5. Nucleic Acids Res. 2015;43(1):373–84. https://doi.org/10.1093/nar/gku1276.CrossRefPubMed

107.

Yang C. ToxPoint: dissecting functional RNA modifications in responses to environmental exposure-mechanistic toxicology research enters a new era. Toxicol Sci. 2020;174(1):1–2. https://doi.org/10.1093/toxsci/kfz252.CrossRefPubMedPubMedCentral

Title: The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis
Authors: Mohammad Burhan Uddin
Zhishan Wang
Chengfeng Yang
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2021
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-021-01356-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2

Cancer-associated fibroblast-derived gene signatures determine prognosis in colon cancer patients

Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade

Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models

The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer